Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (00874.HK) Latest Company News

Aug 27, 2026, 05:30 UTC
Singapore biotech company LionTCR will work with Guangzhou Pharmaceutical Holdings to develop and accelerate the clinical translation of TCR-T cell therapies.
Source:
- sbr.com.sg
Aug 25, 2026, 08:21 UTC
Baiyunshan and other parties jointly established Hongyang Health Technology (Yangzhou) Co., Ltd., a health technology company in Yangzhou, China, with Li Jin as legal representative, covering cosmetics production and daily necessities sales.
Source:
- finance.sina.cn
Aug 24, 2026, 08:10 UTC
Baiyunshan's wholly-owned subsidiary Guangzhou Baiyunshan Mingxing Pharmaceutical received approval from China's National Medical Products Administration for its norepinephrine bitartrate injection (1ml:2mg) to pass generic drug consistency evaluation, with changes to formulation, production process, registration standards, packaging, and labeling also approved.
Source:
- finance.sina.cn
Aug 23, 2026, 04:00 UTC
Guangzhou Pharmaceutical Group, the parent of Baiyunshan, announced it will invest 20 billion yuan in R&D and 30 billion yuan in industrial investment and M&A during the 15th Five-Year Plan period.
Source:
- wap.eastmoney.com
Aug 21, 2026, 12:13 UTC
Baiyunshan proposed a cash dividend of 0.30 yuan per share (pre-tax) for the first half of 2026.
Source:
- finance.sina.cn
- aastocks.com
Aug 21, 2026, 12:13 UTC
Baiyunshan announced its first-half 2026 results: net profit attributable to shareholders was 2.096 billion yuan, down 16.70% year-on-year.
Source:
Aug 19, 2026, 08:06 UTC
Baiyunshan's subsidiary Tianxin Pharmaceutical received approval from China's National Medical Products Administration for a supplementary application for citicoline sodium injection, including consistency evaluation and a new specification.
Source:
- finance.sina.cn
Aug 17, 2026, 09:26 UTC
Baiyunshan's subsidiary Guangzhou Baiyunshan Tianxin Pharmaceutical received a drug registration certificate from the Macao SAR government for cefazolin sodium for injection.
Source:
- finance.sina.cn
Aug 12, 2026, 13:51 UTC
Wanglaoji launched two new products, a natural energy electrolyte drink and a natural berry drink, at its WALOVI new product launch event in Guangzhou, and announced new bottle packaging.
Source:
- m.21jingji.com
Jul 31, 2026, 08:32 UTC
The Xingye Yuanyong-Guangzhou Pharmaceutical Accounts Receivable Phase 4 Asset-Backed Special Plan matured and terminated on June 5, 2026, initiating liquidation through July 17, during which fees were paid and distributions made to subordinated holders, leaving the account balance at zero.
Source:
- finance.sina.cn
Jul 28, 2026, 11:57 UTC
Guangzhou Pharmaceutical Group (GP Corp) ranked 467th on the 2026 Fortune Global 500 list, marking its sixth consecutive year on the list.
Source:
- wap.eastmoney.com
Jul 27, 2026, 14:06 UTC
Guangzhou Baiyunshan Hejigong Pharmaceutical Co., Ltd., a subsidiary of Guangzhou Pharmaceutical Holdings Limited, acquired a controlling stake in Beijing Fama Star Pharmaceutical Technology Co., Ltd. for 330 million yuan.
Source:
- finance.sina.cn
Jul 27, 2026, 01:51 UTC
Guangzhou Pharmaceutical Group acquired control of Daan Gene for about 2.418 billion yuan.
Source:
- tmtpost.com
Jul 21, 2026, 09:57 UTC
Guangzhou Pharmaceutical Group, through its wholly-owned subsidiary Baiyunshan, jointly established Guangyao Damei Biotechnology Co., Ltd. with Xiamen Haizhi Future, targeting the cosmetics sector.
Source:
- tmtpost.com
Jul 20, 2026, 07:54 UTC
Guangzhou Pharmaceutical (Guangyao) Group, via its subsidiary Guangyao Digital Technology, together with Huawei and Shouxin Molecule, launched a full-stack domestic AI drug R&D platform that was selected as a national-level case by the Ministry of Industry and Information Technology.
Source:
- m.21jingji.com
Jul 15, 2026, 05:56 UTC
Guangzhou Wanglaoji Big Health Industry Co., Ltd. removed its deputy general manager in charge of sales, Wang Ping, from his post.
Source:
- m.21jingji.com
Jul 10, 2026, 14:00 UTC
Baiyunshan Pharmaceutical announced that its subsidiary Guangzhou Pharmaceutical plans to issue up to 920 million new shares via capital increase and share expansion to raise between RMB 1.0 billion and RMB 3.0 billion from strategic investors.
Source:
- m.21jingji.com
Jul 9, 2026, 10:35 UTC
Baiyunshan's subsidiary Tianxin Pharmaceutical received regulatory approval for its drug Dexamethasone Sodium Phosphate Injection to pass consistency evaluation.
Source:
- finance.sina.cn
Jul 7, 2026, 07:05 UTC
Baiyunshan and Xiamen Haizhi Weilai Investment jointly established a biotechnology company, Guangyao Damei Biotechnology (Guangzhou) Co., Ltd., with a registered capital of 20 million yuan.

00874.HK

Singapore biotech company LionTCR will work with Guangzhou Pharmaceutical Holdings to develop and accelerate the clinical translation of TCR-T cell therapies.

Baiyunshan and other parties jointly established Hongyang Health Technology (Yangzhou) Co., Ltd., a health technology company in Yangzhou, China, with Li Jin as legal representative, covering cosmetics production and daily necessities sales.

Guangzhou Pharmaceutical Group, the parent of Baiyunshan, announced it will invest 20 billion yuan in R&D and 30 billion yuan in industrial investment and M&A during the 15th Five-Year Plan period.

Baiyunshan proposed a cash dividend of 0.30 yuan per share (pre-tax) for the first half of 2026.

Baiyunshan announced its first-half 2026 results: net profit attributable to shareholders was 2.096 billion yuan, down 16.70% year-on-year.

Baiyunshan's subsidiary Tianxin Pharmaceutical received approval from China's National Medical Products Administration for a supplementary application for citicoline sodium injection, including consistency evaluation and a new specification.

Baiyunshan's subsidiary Guangzhou Baiyunshan Tianxin Pharmaceutical received a drug registration certificate from the Macao SAR government for cefazolin sodium for injection.

Wanglaoji launched two new products, a natural energy electrolyte drink and a natural berry drink, at its WALOVI new product launch event in Guangzhou, and announced new bottle packaging.

The Xingye Yuanyong-Guangzhou Pharmaceutical Accounts Receivable Phase 4 Asset-Backed Special Plan matured and terminated on June 5, 2026, initiating liquidation through July 17, during which fees were paid and distributions made to subordinated holders, leaving the account balance at zero.

Guangzhou Pharmaceutical Group (GP Corp) ranked 467th on the 2026 Fortune Global 500 list, marking its sixth consecutive year on the list.

Guangzhou Baiyunshan Hejigong Pharmaceutical Co., Ltd., a subsidiary of Guangzhou Pharmaceutical Holdings Limited, acquired a controlling stake in Beijing Fama Star Pharmaceutical Technology Co., Ltd. for 330 million yuan.

Guangzhou Pharmaceutical Group acquired control of Daan Gene for about 2.418 billion yuan.

Guangzhou Pharmaceutical Group, through its wholly-owned subsidiary Baiyunshan, jointly established Guangyao Damei Biotechnology Co., Ltd. with Xiamen Haizhi Future, targeting the cosmetics sector.

Guangzhou Pharmaceutical (Guangyao) Group, via its subsidiary Guangyao Digital Technology, together with Huawei and Shouxin Molecule, launched a full-stack domestic AI drug R&D platform that was selected as a national-level case by the Ministry of Industry and Information Technology.

Guangzhou Wanglaoji Big Health Industry Co., Ltd. removed its deputy general manager in charge of sales, Wang Ping, from his post.

Baiyunshan Pharmaceutical announced that its subsidiary Guangzhou Pharmaceutical plans to issue up to 920 million new shares via capital increase and share expansion to raise between RMB 1.0 billion and RMB 3.0 billion from strategic investors.

Baiyunshan's subsidiary Tianxin Pharmaceutical received regulatory approval for its drug Dexamethasone Sodium Phosphate Injection to pass consistency evaluation.

Baiyunshan and Xiamen Haizhi Weilai Investment jointly established a biotechnology company, Guangyao Damei Biotechnology (Guangzhou) Co., Ltd., with a registered capital of 20 million yuan.